Anti-Hu CD19 PerCP-Cy™5.5

*Lin CW, Liu TY, Chen SU, Wang KT, Medeiros LJ, Hsu SM: CD94 1A transcripts characterize lymphoblastic lymphoma/leukemia of immature natural killer cell origin with distinct clinical features. Blood. 2005 Nov 15;106 (10) :3567-74. Epub 2005 Jul 26., URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16046525&query_hl=14&itool=pubmed_DocSum , *Stehlíková O, Chovancová J, Tichý B, Krejčí M, Brychtová Y, Panovská A, Francová Skuhrová H, Burčková K, Borský M, Loja T, Mayer J, Pospíšilová S, Doubek M: Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8-color flow cytometry protocol in routine hematological practice. Int J Lab Hematol. 2013 Sep 13. doi: 10.1111/ijlh.12149., URL: http://www.ncbi.nlm.nih.gov/pubmed/24028768 , *Kayserova J, Vcelakova J, Stechova K, Dudkova E, Hromadkova H, Sumnik Z, Kolouskova S, Spisek R, Sediva A: Decreased dendritic cell numbers but increased TLR9-mediated interferon-alpha production in first degree relatives of type 1 diabetes patients. Clin Immunol. 2014 Jul;153 (1) :49-55., URL: http://www.ncbi.nlm.nih.gov/pubmed/24709112 , *Elias F, Flo J, Lopez RA, Zorzopulos J, Montaner A, Rodriguez JM: Strong cytosine-guanosine-independent immunostimulation in humans and other primates by synthetic oligodeoxynucleotides with PyNTTTTGT motifs. J Immunol. 2003 Oct 1;171 (7) :3697-704. , URL: https://www.ncbi.nlm.nih.gov/pubmed/14500668?dopt=, *Allen JS, Pang K, Skowera A, Ellis R, Rackham C, Lozanoska-Ochser B, Tree T, Leslie RD, Tremble JM, Dayan CM, Peakman M: Plasmacytoid dendritic cells are proportionally expanded at diagnosis of type 1 diabetes and enhance islet autoantigen presentation to T-cells through immune complex capture. Diabetes. 2009 Jan;58 (1) :138-45., URL: https://pubmed.ncbi.nlm.nih.gov/18835928/, *Weijler L, Kowarsch F, Wödlinger M, Reiter M, Maurer-Granofszky M, Schumich A, Dworzak MN: UMAP based anomaly detection for minimal residual disease quantification within acute myeloid leukemia. Cancers (Basel) 2022 Feb 11;14 (4) :898., URL: https://pubmed.ncbi.nlm.nih.gov/35205645/

*Shi X, Xie C, Chang S, Zhou XJ, Tedder T, Mohan C: CD19 hyperexpression augments Sle1-induced humoral autoimmunity but not clinical nephritis. Arthritis Rheum. 2007 Sep;56 (9) :3057-69., URL: https://pubmed.ncbi.nlm.nih.gov/17763445/, *van Zelm MC, Reisli I, van der Burg M, Castaño D, van Noesel CJ, van Tol MJ, Woellner C, Grimbacher B, Patiño PJ, van Dongen JJ, Franco JL: An antibody-deficiency syndrome due to mutations in the CD19 gene. N Engl J Med. 2006 May 4;354 (18) :1901-12., URL: https://pubmed.ncbi.nlm.nih.gov/16672701/, *Inabe K, Kurosaki T: Tyrosine phosphorylation of B-cell adaptor for phosphoinositide 3-kinase is required for Akt activation in response to CD19 engagement. Blood. 2002 Jan 15;99 (2) :584-9., URL: https://pubmed.ncbi.nlm.nih.gov/11781242/, *Fujimoto M, Poe JC, Jansen PJ, Sato S, Tedder TF: CD19 amplifies B lymphocyte signal transduction by regulating Src-family protein tyrosine kinase activation. J Immunol. 1999 Jun 15;162 (12) :7088-94., URL: https://pubmed.ncbi.nlm.nih.gov/10358152/

The antibody LT19 reacts with an extracellular epitope of CD19 (B4), a 95 kDa type I transmembrane glycoprotein (immunoglobulin superfamily) expressed on B lymphocytes and follicular dendritic cells; it is lost on plasma cells.